Ian Sherwin

In the last year, Ian has represented a PE/growth-capital firm in selling a subsidiary to a major buyer. He previously represented Bristol-Myers in a $13 billion divestiture to another pharma giant in the context of a $90-billion acquisition. And he represented a third company in a multibillion-dollar acquisition agreement.

Ian focuses on executive compensation and employee benefits matters in connection with M&A and other transactions, primarily with respect to private equity sponsors and their portfolio companies. Ian also advises clients on the design, implementation and disclosure of, and taxation relating to, equity and cash-based incentive compensation, deferred compensation programs, retention and transaction-based bonus programs and the negotiation of executive employment, change in control and separation agreements. Ian is a capable savant of the taxation rules governing executive compensation.